Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers

The goal of this clinical research study is to find the highest tolerable dose of TGFBR-2 KO CD70 CAR NK (TRICK-NK) in combination with 2 doses of T-Dxd that can be given to participants who have advanced breast cancer. The safety of TRICK-NK will also be studied. The goal of Part 1 (dose escalation) of this clinical research study is to find the highest tolerable dose of TRICK-NK (in combination with T-Dxd) that can be given to participants who have advanced breast cancer. The goal of Part 2 (dose expansion) of this clinical research study is to learn if the dose of TRICK-NK found in Part 1

Trial Details

NCT ID
NCT07553390
Phase
PHASE1
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells
  • Trastuzumab deruxtecan (T-DXd)
  • Rimiducid
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Patients must have histologically confirmed breast cancer that is metastatic or unresectable and for which standard curative or palliative measures…
  • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter t…
  • Age ≥18 years. Because no dosing or adverse event data are currently available on the use of TRICK-NK cells in patients \<18 years of age, children…
  • For patients with triple negative subtype (TNBC, ER\<1%, PR 1%, HER2 negative per ASCO/ CAP 2018 guideline), must have received at least one dose o…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →